http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : Deog Keom Kim (검색결과 4 건)
- 무료
- 기관 내 무료
- 유료
-
The effect of metformin on culture conversion in tuberculosis patients with diabetes mellitus
이예진,Sung Koo Han,Ju Hee Park,Jung Kyu Lee,Deog Keom Kim,Hee Soon Chung,Eun Young Heo 대한내과학회 2018 The Korean Journal of Internal Medicine Vol.33 No.5
Background/Aims: Patients with diabetes mellitus (DM) and tuberculosis (TB) have increased morbidity and a high risk of treatment failure or recurrence. It is important to manage both diseases simultaneously. Among anti-diabetic drugs, metformin inhibits intracellular growth of mycobacteria. Therefore, we examined the effects of metformin on TB treatment, especially in patients with DM. Methods: This retrospective cohort study included patients with culture-positive pulmonary TB diagnosed between 2011 and 2012. The primary study outcome was sputum culture conversion after 2 months of treatment. Results: Of 499 patients diagnosed with culture-positive pulmonary TB, 105 (21%) had DM at diagnosis. Among them, 62 (59.5%) were treated with metformin. Baseline characteristics, except for the presence of chronic renal disease, were not significantly different between the metformin and non-metformin groups. Metformin treatment had no significant effect on sputum culture conversion (p = 0.60) and recurrence within 1 year after TB treatment completion (p = 0.39). However, metformin improved the sputum culture conversion rate in patients with cavitary pulmonary TB, who have higher bacterial loads (odds ratio, 10.8; 95% confidence interval, 1.22 to 95.63). Conclusions: Among cavitary pulmonary TB patients with DM, metformin can be an effective adjunctive anti-TB agent to improve sputum culture conversion after 2 months of treatment.
-
The effect of metformin on culture conversion in tuberculosis patients with diabetes mellitus
( Ye-jin Lee ),( Sung Koo Han ),( Ju Hee Park ),( Jung Kyu Lee ),( Deog Keom Kim ),( Hee Soon Chung ),( Eun Young Heo ) 대한내과학회 2018 The Korean Journal of Internal Medicine Vol.33 No.5
Background/Aims: Patients with diabetes mellitus (DM) and tuberculosis (TB) have increased morbidity and a high risk of treatment failure or recurrence. It is important to manage both diseases simultaneously. Among anti-diabetic drugs, metformin inhibits intracellular growth of mycobacteria. Therefore, we exam ined the effects of metformin on TB treatment, especially in patients with DM. Methods: This retrospective cohort study included patients with culture-positive pulmonary TB diagnosed between 2011 and 2012. The primary study outcome was sputum culture conversion after 2 months of treatment. Results: Of 499 patients diagnosed with culture-positive pulmonary TB, 105 (21%) had DM at diagnosis. Among them, 62 (59.5%) were treated with metformin. Baseline characteristics, except for the presence of chronic renal disease, were not significantly different between the metformin and non-metformin groups. Met formin treatment had no significant effect on sputum culture conversion (p = 0.60) and recurrence within 1 year after TB treatment completion (p = 0.39). However, metformin improved the sputum culture conversion rate in patients with cavitary pulmonary TB, who have higher bacterial loads (odds ratio, 10.8; 95% confidence interval, 1.22 to 95.63). Conclusions: Among cavitary pulmonary TB patients with DM, metformin can be an effective adjunctive anti-TB agent to improve sputum culture conversion after 2 months of treatment.
-
( Ye Jin Lee ),( Seo Young Yun ),( Tae Yun Park ),( Jung Kyu Lee ),( Deog Keom Kim ),( Hee Soon Chung ),( Eun Young Heo ) 대한결핵 및 호흡기학회 2019 대한결핵 및 호흡기학회 추계학술대회 초록집 Vol.127 No.-
Background: Programmed death ligand 1 (PD-L1) expression is not truly reflected response of immunotherapy. Thus, tumor mutational burden is new biomarker for predict response of immunotherapy. However, sufficient quantity or quality tumor samples must be obtained, so this is limitation. Therefore, we investigated whether high serum absolute lymphocyte count (ALC) is predictive biomarker for immunochemotherapy response regardless of PD-L1 immunohistochemistry stain among lung cancer patients. Materials and Methods: We retrospectively analyzed the medical charts of lung cancer patients who treated with immunotherapy (pembrolizumab, nivoluamb, ipilimumab, atezolizumab) at Seoul National University Hospital between April 2016 and March 2019. We evaluated correlation the serum absolute lymphocyte count (ALC) with the progression free survival (PFS) using cox proportional hazard model. ALC at before and after one month of immunotherapy was collected. ALC are presented as medians with interquartile ranges (IQRs). Quartile group of ALC was compared using Kruskal-Wallis statistical test. Results: Total 236 patients treated with immunotherapy for lung cancer. Median follow up period was 4.7 months. During the period, 137 (58.1%) had progression of disease. Progression event was significantly lower for post-treatment ALC Q2-4 than Q1 in our adjusted model (Q4 HR 0.42 95% CI 0.24-0.71, p = 0.001). Overall survival was also showed similar results. Association with total or serious adverse event and ALC was not observed in this study. Conclusion: In this study, we revealed that increased post treatment ALC was associated with favor progression free and overall survival among lung cancer patients who treated with immunotherapy. Therefore, ALC could predict response of immune checkpoint inhibitor for lung cancer patients.
-
( Hye-rin Kang ),( Ye Jin Lee ),( Seo Young Yoon ),( Ha Youn Lee ),( Tae Yun Park ),( Jung Kyu Lee ),( Eun Young Heo ),( Seung Ho Choi ),( Hee Soon Chung ),( Deog Keom Kim ) 대한결핵 및 호흡기학회 2019 대한결핵 및 호흡기학회 추계학술대회 초록집 Vol.127 No.-
Background: Although gastroesophageal reflux disease (GERD) associates with many respiratory disorders such as bronchial asthma, chronic cough, chronic bronchitis, and idiopathic pulmonary fibrosis, the association between GERD and lung functions is controversial and its association with lung function decline was rarely reported. This study was performed to evaluate the association of endoscopically diagnosed esophagitis (e-GERD) and lung function changes. Methods: From the Gene-environment interaction and phenotype (GENIE) cohort at Seoul national university hospital Gangnam center, patients with more than two spirometry results and two spirometry- matched endoscopy were included. E-GERD was defined when the reflux esophagitis was found persistently in two discrete endoscopic examinations. Spirometric changes of patients with e-GERD were compared with matched patients without e-GERD (ratio, 1:4). Annual FEV1 or FVC changes from baseline were estimated and compared with linear mixed regression model. Severity of e-GERD was assessed with Los Angeles (LA) classification. Results: Totally 1,050 patients (210 patients with e-GERD and their matched 840 controls) were included in final analysis. Median follow-up duration for spirometry was 6 years. In e-GERD patients, mild disease (LA, A grade) was most common (165 patients, 78.6%). The adjusted annual FEV1 change in patients with e-GERD was -51.8 ml/year while it decreased by 46.8 ml/year in controls (p=0.270). The adjusted annual FVC decline was numerically larger in GERD group than in controls without statistical significance (-55.8ml/year vs. -50.5ml/year, p=0.215). With the increase of severity in e-GERD, annual decline of FEV1 became larger in trend (-51 ml/year in LA classification A, -54.8 ml/ year in LA classification B, and -61.4 ml/year in LA classification C) without statistical significance. Also the annual decline of FVC showed similar trend. Conclusion: Comparing with controls, the annual decline of FEV1 or FVC were not statistically different in patients with e-GERD despite the more declining trend.
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
